SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are seeing significant activity driven by a strong quarterly earnings report that featured a revenue beat and upward guidance revisions. Investors are actively discussing the company's path to consistent profitability and the implications of its growing user base of over 100 million households as it navigates competition in the streaming ad space.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as investors focus on its integration into the Solana ecosystem and its role as a key decentralized AI infrastructure project. Community sentiment remains highly bullish, with many focusing on its long-term potential as an AI supercomputer while actively debating staking strategies and the importance of subnet developments.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing significant community attention as investors debate its potential for future gains following a period of volatility and market correction. While some traders view current price levels as an accumulation opportunity, others are focused on speculative catalysts and the coin's historical role as a bellwether for broader meme coin liquidity.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community is rallying around the $UPDOG.X project as it celebrates its two-year anniversary, fueled by its ongoing presence on the Jupiter strict list and active whale accumulation. Meanwhile, conversations surrounding $JUP.X are polarized, with some users highlighting its lending and staking utility while others voice concerns over platform stability and trading frustrations.

Anthropic

Anthropic is trending as investors and the community closely track its path toward a highly anticipated IPO, fueled by massive capital raises and intense competition with OpenAI. The discourse is heavily focused on the company's aggressive infrastructure scaling, its strategic partnerships with tech giants, and the ongoing debate regarding the government's role in regulating powerful AI systems.

OpenAI

OpenAI is trending as investors closely track its confidential IPO filing and ongoing discussions regarding a potential U.S. government equity stake, while the community debates the firm's heavy infrastructure spending and long-term valuation prospects compared to rivals like Anthropic. Traders are also actively discussing the company's aggressive acquisition of cloud infrastructure startups and the ripple effects these strategic moves have on the broader AI hardware and software ecosystem.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

The 401jK community is actively rallying around the upcoming NFT drop on June 20th and the launch of a custom mockchain to fuel their 'Resist & Retire' narrative. Holders are framing the project as a pure belief asset and a satirical alternative to traditional retirement plans, sparking ongoing discussions about the project's long-term sustainability compared to broader market trends.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors digest the commercial launch of NEREUS for motion sickness while debating potential buyout interest from major pharma players like Eli Lilly. The community is actively discussing the stock's pipeline potential as a GLP-1 adjunct treatment despite persistent concerns regarding management's spending and confrontational regulatory strategy.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

Financials are facing significant pressure as investors rotate away from the sector amidst rising concerns over private credit exposure and broader economic volatility. While the fund is currently testing critical support levels, the community remains divided, with some monitoring for a potential technical bounce while others warn of structural weaknesses signaling a deeper downturn.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

AMGN is actively capturing investor attention as its robust pipeline and strategic acquisitions, such as the recent deal to lower U.S. drug prices while expanding manufacturing, drive renewed growth expectations. The community is focused on the potential impact of its obesity drug MariTide and the ongoing expansion of its cardiometabolic portfolio, viewing these developments as key offsets to long-term patent pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone

Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone...

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

Key PointsFCPM III sold 818,460 shares of Dyne Therapeutics last quarter; the estimated transaction value was $14.11 million based on average prices...

Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy

DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dystrophy.

Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients

DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystrophy patients amenable to exon 51 skipping.

DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside

Equity

Dyne said it plans to submit an application seeking accelerated approval of z-rostudirsen to the U.S. Food and Drug Administration later this quarter.


Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

Key PointsSaturn V sold 822,007 shares of Dyne Therapeutics in the first quarter; the estimated transaction value was $14.17 million based on quarterly average prices...

Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know

Dyne Therapeutics (DYN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Dyne Therapeutics Q1 Net Loss Widens

(RTTNews) - Dyne Therapeutics, Inc. (DYN) reported Monday that net loss for the first quarter was $120.85 million or $0.73 per share, compared to net loss of $115.36 million or $1.05 per share in the prior-year quarter...

Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,600 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 11,600 shares of the business's stock in a transaction on Tuesday, May 5th. The shares were sold at an average price...

Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,904 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 11,904 shares of the company's stock in a transaction on Monday, May 4th. The stock was sold at an average price of...

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

DYNDyne Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DYN News